Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 1.84 -0.20 (-9.66%)
As of 06:55 AM Eastern
Compare

GENF vs. COIL, C4XD, DDDD, SBTX, and IMM

Should you buy Genflow Biosciences stock or one of its competitors? Genflow Biosciences's main competitors and comparable companies include Roquefort Therapeutics (COIL), C4X Discovery (C4XD), 4D pharma (DDDD), SkinBioTherapeutics (SBTX), and ImmuPharma (IMM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Genflow Biosciences has a net margin of -170.64% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 332.06% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Genflow Biosciences -170.64%332.06%-58.66%

1.9% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, indicating that its stock price is 130% more volatile than the broader market.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Genflow Biosciences Neutral

Summary

Roquefort Therapeutics beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

C4X Discovery has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, meaning that its share price is 130% more volatile than the broader market.

52.1% of C4X Discovery shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 27.1% of C4X Discovery shares are owned by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences -170.64%332.06%-58.66%

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

Genflow Biosciences (LON:GENF) and 4D pharma (LON:DDDD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 26.8% of 4D pharma shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by company insiders. Comparatively, 12.2% of 4D pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genflow Biosciences has a beta of 2.297, suggesting that its share price is 130% more volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, suggesting that its share price is 163% more volatile than the broader market.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
4D pharma Neutral

Genflow Biosciences has higher earnings, but lower revenue than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
4D pharma£718K0.00-£31.94M-£15.40N/A

4D pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
4D pharma N/A -89.48%-42.64%

Summary

4D pharma beats Genflow Biosciences on 6 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to SkinBioTherapeutics?

Genflow Biosciences (LON:GENF) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
SkinBioTherapeutics Neutral

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

SkinBioTherapeutics has a net margin of -8.73% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Genflow Biosciences has a beta of 2.297, suggesting that its share price is 130% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market.

Genflow Biosciences has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
SkinBioTherapeutics£5.23M4.96-£3.71M-£0.16N/A

Summary

Genflow Biosciences beats SkinBioTherapeutics on 6 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to ImmuPharma?

ImmuPharma (LON:IMM) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

ImmuPharma has a beta of 3.02, meaning that its share price is 202% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.297, meaning that its share price is 130% more volatile than the broader market.

In the previous week, ImmuPharma had 2 more articles in the media than Genflow Biosciences. MarketBeat recorded 2 mentions for ImmuPharma and 0 mentions for Genflow Biosciences. ImmuPharma's average media sentiment score of 0.40 beat Genflow Biosciences' score of 0.00 indicating that ImmuPharma is being referred to more favorably in the media.

Company Overall Sentiment
ImmuPharma Neutral
Genflow Biosciences Neutral

ImmuPharma is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuPharmaN/AN/A-£2.51M-£0.37N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

6.1% of ImmuPharma shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 6.2% of ImmuPharma shares are owned by insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImmuPharma has a net margin of 3,519.56% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuPharma3,519.56% -353.21% -43.00%
Genflow Biosciences -170.64%332.06%-58.66%

Summary

ImmuPharma beats Genflow Biosciences on 6 of the 11 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£10.44M£3.74B£7.08B£2.89B
Dividend YieldN/A3.76%2.58%6.09%
P/E Ratio-5.5510.36268.52368.54
Price / SalesN/A1,273.20652.4983,661.83
Price / Cash3.00102.9470.5927.89
Price / Book7.4317.8213.147.24
Net Income-£1.76M-£13.23M£3.45B£5.89B
7 Day Performance2.39%3.00%1.83%1.25%
1 Month Performance-6.68%1.42%0.92%2.72%
1 Year Performance177.56%55.38%67.70%70.10%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 1.84
-9.7%		N/A+236.6%£10.44MN/AN/A5
COIL
Roquefort Therapeutics
N/AGBX 9.55
+0.3%		N/A-38.3%£40.76MN/AN/A9
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718KN/A106
SBTX
SkinBioTherapeutics
N/AGBX 11
-1.0%		N/A-32.5%£28.51M£5.23MN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel